Infographic: Psoriasis (PsO)
An overview of the PsO advanced therapy and systemic patient
Our PsO market snapshot offers an introduction to the real world patient data collected by our Therapy Watch PsO study. The snapshot features profile data for patients treated with advanced therapy agents and systemic agents.
Scratching the surface: unmet needs in psoriasis
Director Mariel Metcalfe shares some key findings from a recent Living with psoriasis study conducted in Europe, which is now available to purchase
Psoriasis is a skin condition but its impact goes much further than skin-deep. The late US novelist John Updike, who had psoriasis from the age of six, talked about being ‘At War with my Skin’.
The martial metaphor is no exaggeration. Updike hesitated to use the term ‘disease’ for something “not contagious, painful, or debilitating”. Yet his psoriasis still had “the volatility of a disease, the sense of another presence co-occupying your body and singling you out from the happy herds of healthy, normal, mankind”.
What next for the treatment of Psoriasis in Europe?
Research Director Laurent Chanroux investigates the changing market dynamics in Psoriasis in Europe.
Over the last decade, systemic biologic therapies for Psoriasis (PsO) have become widespread and the development of biological therapies has revolutionized the treatment of the disease. A chronic autoimmune disease, psoriasis has an estimated prevalence of 2.5% in Europe, representing approximately 15 million people, with 20–25% of these suffering from severe disease.
AAD Conference 2016
Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients
We were delighted to present a poster at the 74th annual meeting of the American Academy of Dermatology, earlier this month. The poster, which is entitled: ‘A real world review of treatment duration and persistence among European psoriasis patients’ is authored by Research Director, Laurent Chanroux and Research Executive, Lauren Royel.
2015: a good year for psoriasis drug development?
Psoriasis (PsO) is a chronic immune-mediated disease estimated to affect more than 125 million people worldwide.
Psoriasis (PsO) is a chronic immune-mediated disease estimated to affect more than 125 million people worldwide. The condition is characterised by thick and extensive skin lesions (plaques), which can cause itching, scaling, and pain. These symptoms can often negatively impact patients’ quality of life, both psychosocially and physically, making daily functioning more difficult and increasing the risk for other chronic illnesses. Although a number of treatment options exist for PsO, there continue to be significant unmet needs in the market